Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers
Clinical Transplantation · 2023
DOI: 10.1111/ctr.14893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Kevin A Reininger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hennepin County Medical Center, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post‐transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism phenotypes on the number of tacrolimus dose adjustments and troughs in the first 6 months post‐transplant was evaluated in 78 recipients (64% Caucasians). Time to first therapeutic concentration, percentage of time in therapeutic range (TTR), and estimated glomerular filtration rate (eGFR) were also evaluated. Fifty‐five kidney transplant recipients were CYP3A5 poor metabolizers (PM), 17 were intermediate metabolizers (IM), and 6 were extensive metabolizers (EM). Compared to PMs, EMs/IMs had significantly more dose adjustments (6.1 vs. 8.1, p = .015). Overall, 33.82% of trough measurements resulted in a dose change. There was no difference in the number of tacrolimus trough measurements between PMs and EM/IMs. The total daily tacrolimus dose requirements were higher in EMs and IMs compared to PMs (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
- Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
- Division of Nephrology, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Nephrology, University of Nebraska, Omaha, Nebraska, USA.
ORCID-Profile: Kevin A Reininger, Guillaume Onyeaghala, Teresa Anderson-Haag, David S Schladt, Baolin Wu, Weihua Guan, Casey R Dorr, Rory P Remmel, Roslyn Mannon, Arthur J Matas, William S Oetting, Paul Stahler, Ajay K Israni, Pamala A Jacobson
Förderung
- NIAID NIH HHS
Zitieren
APA
Reininger, K. A., Onyeaghala, G., Anderson-Haag, T., Schladt, D. S., Wu, B., Guan, W., Dorr, C. R., Remmel, R. P., Mannon, R., Matas, A. J., Oetting, W. S., Stahler, P., Israni, A. K., & Jacobson, P. A. (2023). Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers. Clinical Transplantation. https://doi.org/10.1111/ctr.14893
Vancouver
Reininger KA, Onyeaghala G, Anderson-Haag T, Schladt DS, Wu B, Guan W, et al. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers. Clinical Transplantation. 2023. doi:10.1111/ctr.14893
BibTeX
@article{Reininger2023,
author = {Reininger, Kevin A and Onyeaghala, Guillaume and Anderson-Haag, Teresa and Schladt, David S and Wu, Baolin and Guan, Weihua and Dorr, Casey R and Remmel, Rory P and Mannon, Roslyn and Matas, Arthur J and Oetting, William S and Stahler, Paul and Israni, Ajay K and Jacobson, Pamala A},
title = {Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.14893}
}
EUVIMED